Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy.

BACKGROUND The aim was to identify predictors of outcome in patients with localized prostate cancer treated with external beam radiotherapy (EBRT), with or without androgen deprivation therapy (ADT). MATERIALS AND METHODS A total of 448 patients with prostate cancer received EBRT alone (n = 361, group 1) or ADT followed by EBRT (n = 87, group 2). In group 2, ADT was initiated 3 months before EBRT. After baseline prostate-specific antigen (PSA) determination (PSA(preRT)), PSA was assessed during the 6th week of the EBRT course (PSA(6wRT)) in group 1. In group 2, PSA was measured again 3 months after the start of ADT, before EBRT (PSA(ADT-preRT)). RESULTS In group 1, median PSA(6wRT)/PSA(preRT) was 0.72 and median prostate-specific antigen velocity (PSAV) was -1.5 ng/ml/month. In the multivariate analysis, prognostic groups and PSA(6wRT)/PSA(preRT) (or PSAV) independently predicted biochemical failure (BF), clinical failure (CF), and prostate cancer-specific survival. In group 2, the median PSA(ADT-preRT) was 1.3 ng/ml. In the high-risk group, an undetectable PSA(ADT-preRT) (< or =0.2 ng/ml) predicted BF (P < 0.01) and CF (P = 0.007). CONCLUSION A PSA decline 6 weeks after the start of EBRT when used as monotherapy and 3 months after the start of ADT in patients treated with combined ADT and EBRT is predictive of progression and specific survival.

[1]  W. Lowrance,et al.  Long‐term follow‐up of 3‐month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial , 2010, BJU international.

[2]  J. Crook,et al.  Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial. , 2010, International journal of radiation oncology, biology, physics.

[3]  S. Fosså,et al.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009, The Lancet.

[4]  M. Gleave,et al.  Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. , 2008, The Journal of urology.

[5]  R de Crevoisier,et al.  The postchemotherapy PSA surge syndrome. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  D. Grignon,et al.  Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Renshaw,et al.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. , 2008, JAMA.

[8]  A. Hanlon,et al.  Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[9]  J. O’Sullivan,et al.  Failure to achieve a PSA level , 2007, International journal of radiation oncology, biology, physics.

[10]  A. Partin,et al.  Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Tyldesley,et al.  Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy. , 2007, International journal of radiation oncology, biology, physics.

[12]  H. Sandler,et al.  Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02. , 2006, International journal of radiation oncology, biology, physics.

[13]  E. Venkatraman,et al.  Evaluation of postradiotherapy PSA patterns and correlation with 10-year disease free survival outcomes for prostate cancer. , 2006, International journal of radiation oncology, biology, physics.

[14]  A. Hanlon,et al.  A Prostate Specific Antigen (PSA) Bounce Greater Than 1.4 ng/mL Is Clinically Significant After External Beam Radiotherapy for Prostate Cancer , 2006, American journal of clinical oncology.

[15]  D. Kuban,et al.  Biochemical and clinical significance of the posttreatment prostate‐specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone , 2006, Cancer.

[16]  C. Tangen,et al.  Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[18]  T. Pickles,et al.  Rising prostate-specific antigen values during neoadjuvant androgen deprivation therapy: The importance of monitoring. , 2006, International journal of radiation oncology, biology, physics.

[19]  D. Waltregny,et al.  Prognostic value of PSA nadir < or =4 ng/mL within 4 months of high-dose radiotherapy for locally advanced prostate cancer. , 2006, International journal of radiation oncology, biology, physics.

[20]  D. Kuban,et al.  First-year PSA kinetics and minima after prostate cancer radiotherapy are predictive of overall survival. , 2005, International journal of radiation oncology, biology, physics.

[21]  D. Kuban,et al.  PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. , 2004, International journal of radiation oncology, biology, physics.

[22]  M. Blute,et al.  Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. , 2005, The Journal of urology.

[23]  A. D'Amico,et al.  Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Tomasz Burzykowski,et al.  Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Kuban,et al.  Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer? , 2005, Urology.

[26]  A. Renshaw,et al.  Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .

[27]  E. Venkatraman,et al.  Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Gasser,et al.  Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Manola,et al.  6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. , 2004, JAMA.

[30]  Ming-Hui Chen,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2004, The New England journal of medicine.

[31]  J. Hanley,et al.  Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. , 2004, Journal of Urology.

[32]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[33]  A. Hanlon,et al.  Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[34]  M. Gleave,et al.  Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. , 2001, The Journal of urology.

[35]  D. Kuban,et al.  Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. , 1999, JAMA.

[36]  C. Ling,et al.  Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[38]  G. Perry,et al.  Serum prostate-specific antigen profile following radiotherapy for prostate cancer: implications for patterns of failure and definition of cure. , 1998, Urology.

[39]  V. Khoo,et al.  Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. , 1997, International journal of radiation oncology, biology, physics.

[40]  G. Perry,et al.  Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma , 1997, Cancer.

[41]  A. Hanlon,et al.  Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. , 1996, International journal of radiation oncology, biology, physics.